[Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results].
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing the authors' own prior studies without systematic search criteria
What was done
Narrative review summarizing findings from the authors' long-term clinical research on the efficacy of various peptide bioregulators (Timalin, Thymogen, Vilon, Epithalamin, Prostatilen, Cortexin, Retinalamin) for disease prevention and treatment across various age groups, focusing on their use as geroprotectors.
What was found
The abstract reports no quantitative data, statistics, sample sizes, or specific outcome measures.
Why it matters
Provides a summary of the authors' clinical experience and conceptual framework regarding peptide bioregulators in aging and disease.
Limits
The abstract provides no methodology, sample size, or quantitative results. As an unsystematic narrative review of the authors' own work, it is subject to high risk of reporting and selection bias.
Cited by
- supports Vladimir Khavinson isolated and sequenced specific regulatory peptides from thymus extracts, including Vilon, Thymogen, and Crystagen.